Randomized placebo-controlled trial assessing the effect of 24-week fenofibrate therapy on circulating markers of abdominal aortic aneurysm: Outcomes from the FAME-2 trial

Journal of the American Heart Association

Volumn 7, Issue 19, 2018, Pages

  Pinchbeck, Jenna L ^a   Moxon, Joseph V ^a   Rowbotham, Sophie E ^a,b,c   Bourke, Michael ^a,d   Lazzaroni, Sharon ^a   Morton, Susan K ^a   Matthews, Evan O ^a   Hendy, Kerolos ^a   Jones, Rhondda E ^a   Bourke, Bernie ^d   Jaeggi, Rene ^a   Favot, Danella ^b   Quigley, Frank ^e   Jenkins, Jason S ^b   Reid, Christopher M ^f,g   Velu, Ramesh ^a,h   Golledge, Jonathan ^a,e,h  

^a JAMES COOK UNIVERSITY   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d Gosford Vascular Services   (Australia)

^e Mater Hospital   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g CURTIN UNIVERSITY   (Australia)

^h TOWNSVILLE HOSPITAL   (Australia)

Author keywords

Abdominal aortic aneurysm; Biomarkers; Clinical trial; Fenofibrate

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; D DIMER; FENOFIBRATE; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KALLISTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPONTIN; OSTEOPROTEGERIN; PLACEBO; RESISTIN; SERINE PROTEINASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT;

ABDOMINAL AORTIC ANEURYSM; AGED; AMINO ACID BLOOD LEVEL; ANEURYSM DIAMETER; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TABLET; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; ABDOMINAL AORTA; BLOOD; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DOSE RESPONSE; ECHOGRAPHY; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; BIOMARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FENOFIBRATE; FOLLOW-UP STUDIES; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; OSTEOPONTIN; SERPINS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 85055617826     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.118.009866     Document Type: Article

References (44)

1. Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D, Krupski WC, Barone GW, Acher CW, Ballard DJ. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med. 1997;126:441–449.
2. Wanhainen A, Hultgren R, Linne A, Holst J, Gottsater A, Langenskiold M, Smidfelt K, Bjorck M, Svensjo S. Outcome of the Swedish nationwide abdominal aortic aneurysm screening program. Circulation. 2016;134:1141–1148.
3. Svensjo S, Mani K, Bjorck M, Lundkvist J, Wanhainen A. Screening for abdominal aortic aneurysm in 65-year-old men remains cost-effective with contemporary epidemiology and management. Eur J Vasc Endovasc Surg. 2014;47:357–365.
4. Khosla S, Morris DR, Moxon JV, Walker PJ, Gasser T, Golledge J. Meta-analysis of peak wall stress in ruptured, symptomatic and intact abdominal aortic aneurysms. Br J Surg. 2014;101:1350–1357.
5. Moxon JV, Parr A, Emeto TI, Walker P, Norman PE, Golledge J. Diagnosis and monitoring of abdominal aortic aneurysm: current status and future prospects. Curr Probl Cardiol. 2010;35:512–548.
6. Cao P; CAESAR Trial Collaborators. Comparison of surveillance vs aortic endografting for small aneurysm repair (CAESAR) trial: study design and progress. Eur J Vasc Endovasc Surg. 2005;30:245–251.
7. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW, Ballard DJ, Messina LM, Gordon IL, Chute EP, Krupski WC, Busuttil SJ, Barone GW, Sparks S, Graham LM, Rapp JH, Makaroun MS, Moneta GL, Cambria RA, Makhoul RG, Eton D, Ansel HJ, Freischlag JA, Bandyk D; Aneurysm Detection and Management Veterans Affairs Cooperative Study Group. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002;346:1437–1444.
8. Ouriel K. The PIVOTAL study: a randomized comparison of endovascular repair versus surveillance in patients with smaller abdominal aortic aneurysms. J Vasc Surg. 2009;49:266–269.
9. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet. 1998;352:1649.
10. UK Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002;346:1445–1452.
11. Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, Mastracci TM, Mell M, Murad MH, Nguyen LL, Oderich GS, Patel MS, Schermerhorn ML, Starnes BW. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018;67:2–77.e72.
12. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, Allmen RS, Vrints CJ. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the diagnosis and treatment of aortic diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2873–2926.
13. Rowbotham SE, Krishna SM, Moran CS, Golledge J. Fenofibrate and telmisartan in the management of abdominal aortic aneurysm. Curr Drug Targets. 2017. Available at: http://www.eurekaselect.com/158698/article. Accessed August 24, 2018.
14. Norman PE, Jamrozik K, Lawrence-Brown MM, Le MT, Spencer CA, Tuohy RJ, Parsons RW, Dickinson JA. Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm. BMJ. 2004;329:1259.
15. Golledge J, Norman PE. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis. 2011;217:57–63.
16. Filippatos TD, Florentin M, Georgoula M, Elisaf MS. Pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2017;10:187–200.
17. Krishna SM, Seto SW, Moxon JV, Rush C, Walker PJ, Norman PE, Golledge J. Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model. Am J Pathol. 2012;181:706–718.
18. Golledge J, Cullen B, Rush C, Moran CS, Secomb E, Wood F, Daugherty A, Campbell JH, Norman PE. Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis. 2010;210:51–56.
19. Rowbotham SE, Bourke B, Bourke M, Jaeggi R, Jenkins J, Moxon JV, Pinchbeck J, Reid C, Velu R, Golledge J. Fenofibrate in the management of abdominal aortic aneurysm (FAME)-2: the study protocol for a randomized, placebocontrolled trial. Int J Clin Trials. 2016;3:217–224.
20. Golledge J, Muller R, Clancy P, McCann M, Norman PE. Evaluation of the diagnostic and prognostic value of plasma D-dimer for abdominal aortic aneurysm. Eur Heart J. 2011;32:354–364.
21. Golledge J, Clancy P, Jamrozik K, Norman PE. Obesity, adipokines, and abdominal aortic aneurysm: Health in Men Study. Circulation. 2007;116:2275–2279.
22. Satoh K, Maniwa T, Oda T, Matsumoto K. Proteomic profiling for the identification of serum diagnostic biomarkers for abdominal and thoracic aortic aneurysms. Proteome Sci. 2013;11:27.
23. Acosta-Martin AE, Panchaud A, Chwastyniak M, Dupont A, Juthier F, Gautier C, Jude B, Amouyel P, Goodlett DR, Pinet F. Quantitative mass spectrometry analysis using pacific for the identification of plasma diagnostic biomarkers for abdominal aortic aneurysm. PLoS One. 2011;6:e28698.
24. Wierzbicki AS. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr Opin Cardiol. 2009;24:372–379.
25. Golledge J, Tsao PS, Dalman RL, Norman P. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation. 2008;118:2382–2392.
26. Cicchetti DV. Guidelines, criteria and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess. 1994;6:284–290.
27. Moxon JV, Liu D, Wong G, Weir JM, Behl-Gilhotra R, Bradshaw B, Kingwell BA, Meikle PJ, Golledge J. Comparison of the serum lipidome in patients with abdominal aortic aneurysm and peripheral artery disease. Circ Cardiovasc Genet. 2014;7:71–79.
28. Smith RK, Quigley F, Tosenovsky P, Velu R, Bradshaw B, Buettner P, Golledge J. Serum homocysteine is associated with the severity of primary chronic venous disease. Phlebology. 2016;31:409–415.
29. Golledge J, Ewels C, Muller R, Walker PJ. Association of chronic kidney disease categories defined with different formulae with major adverse events in patients with peripheral vascular disease. Atherosclerosis. 2014;232:289–297.
30. Ferguson CD, Clancy P, Bourke B, Walker PJ, Dear A, Buckenham T, Norman P, Golledge J. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J. 2010;159:307–313.
31. Morris DR, Singh TP, Moxon JV, Smith A, Stewart F, Jones RE, Golledge J. Assessment and validation of a novel angiographic scoring system for peripheral artery disease. Br J Surg. 2017;104:544–554.
32. National Health and Medical Research Council. Guidance: safety monitoring and reporting in clinical trials involving therapeutic goods. 2016;EH59. ISBN: 978-971-925129-925168-925127
33. Nakamachi T, Nomiyama T, Gizard F, Heywood EB, Jones KL, Zhao Y, Fuentes L, Takebayashi K, Aso Y, Staels B, Inukai T, Bruemmer D. Ppar alpha agonistssuppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Diabetes. 2007;56:1662–1670.
34. Moxon JV, Jones RE, Norman PE, Clancy P, Flicker L, Almeida OP, Hankey GJ, Yeap BB, Golledge J. Plasma ferritin concentrations are not associated with abdominal aortic aneurysm diagnosis, size or growth. Atherosclerosis. 2016;251:19–24.
35. Moxon JV, Ng E, Lazzaroni SM, Boult M, Velu R, Fitridge RA, Golledge J. Circulating biomarkers are not associated with endoleaks after endovascular repair of abdominal aortic aneurysms. J Vasc Surg. 2018;67: 770–777.
36. Golledge J, Moxon J, Pinchbeck J, Anderson G, Rowbotham S, Jenkins J, Bourke M, Bourke B, Dear A, Buckenham T, Jones R, Norman PE. Association between metformin prescription and growth rates of abdominal aortic aneurysms. Br J Surg. 2017;104:1486–1493.
37. Fox J, Weisberg S. An R Companion to Applied Regression. 2nd ed. Thousand Oaks, CA: Sage; 2011.
38. Pinheiro J, Bates D, DebRoy S, Sarkar D; Team RDC. Nlme: linear and nonlinear mixed effects models. R package version 3.1-111. 2013.
39. Celinska-Lowenhoff M, Lowenhoff T, Undas A, Gluszko P. Effects of hypolipemic drugs on the osteoprotegerin—sRANKL system in patients with coronary artery disease. Thromb Haemost. 2007;97:868–870.
40. Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, Thommesen L, Reseland JE. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPAR gamma agonist pioglitazone. BMC Endocr Disord. 2009;9:10.
41. Bicknell CD, Kiru G, Falaschetti E, Powell JT, Poulter NR. An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK). Eur Heart J. 2016;37:3213–3221.
42. Rowbotham SE, Cavaye D, Jaeggi R, Jenkins JS, Moran CS, Moxon JV, Pinchbeck JL, Quigley F, Reid CM, Golledge J. Fenofibrate in the management of abdominal aortic aneurysm (FAME): study protocol for a randomised controlled trial. Trials. 2017;18:1.
43. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.
44. Ling H, Luoma JT, Hilleman D. A review of currently available fenofibrate and fenofibric acid formulations. Cardiol Res. 2013;4:47–55.